$ cat ./records/gates-foundation-funded-m72-tuberculosis-vaccine-shows-50-efficac-2019.txt
Gates Foundation-funded M72 tuberculosis vaccine shows 50% efficacy — first advance in nearly a century
[RECORD.TXT] · cat --full
A Gates Foundation-funded Phase 2b trial of the M72/AS01E vaccine candidate published in the New England Journal of Medicine showed 54% efficacy in preventing active tuberculosis — the first significant TB vaccine advance in nearly 100 years. TB kills approximately 1.5 million people annually. Gates called the result 'extraordinary news' and committed additional funding to Phase 3 trials.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Participated in WEF climate sessions calling for dramatically increased clean energy investment
Next →
Gates Foundation invests $200 million in global mental health research
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.